Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m. Pacific Time. A webcast and replay of the presentation will be available on the "Investor Relations/Events" section of the Company's website at: https://ir.arcturusrx.com/investor-calendar About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR ® lipid-mediated delivery, (ii) STARR ® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive™, the first self-ampli
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.MarketBeat
- European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccinePR Newswire
- European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine [Yahoo! Finance]Yahoo! Finance
- European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineBusiness Wire
- Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 11/7/24 - Beat
ARCT
Sec Filings
- 2/5/25 - Form SCHEDULE
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- ARCT's page on the SEC website